Milestone Scientific Reports Q1 2026 Financial Results with Improved Net Loss and Increased Medical Sales

Milestone Scientific Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $839,853, a significant improvement from the $1,994,586 loss recorded in the same period of 2025. The company's total product sales for the quarter were approximately $2.16 million, down 3% from $2.23 million in the prior year. The decline in revenue was primarily attributed to a 6% decrease in dental product sales, which amounted to $2.05 million, reflecting reduced demand from international distributors amid ongoing geopolitical tensions. In contrast, medical product sales saw a notable increase of 110%, reaching $108,000, compared to $51,000 in the previous year.

The company's gross profit for the quarter was $1.56 million, resulting in a gross margin of approximately 72.3%, slightly down from 73.8% in the prior year. The decrease in gross profit was largely due to lower sales in the dental segment, compounded by cost pressures from tariffs on imported components. However, the medical segment's improved performance partially offset these declines. Total operating expenses decreased significantly to $2.39 million from $3.65 million, driven by reduced selling, general, and administrative expenses, which fell by 27.2% due to lower professional fees and marketing expenditures.

Milestone Scientific's balance sheet as of March 31, 2026, showed total assets of approximately $7.96 million, an increase from $7.81 million at the end of 2025. Current liabilities rose to $4.86 million from $4.13 million, primarily due to increased accounts payable. The company reported cash and cash equivalents of $1.19 million, up from $1.11 million at the end of the previous year. The increase in cash flow from operating activities to $86,842, compared to a cash outflow of $1.01 million in the prior year, indicates improved operational efficiency.

Strategically, Milestone Scientific completed a private placement on April 20, 2026, raising approximately $2.15 million, which included $1.80 million in cash and a reduction of $351,000 in outstanding convertible notes. This funding is intended to bolster the company's liquidity and support ongoing operations. The company continues to focus on expanding the adoption of its Dynamic Pressure Sensing Technology® platform and advancing its medical segment, particularly the CompuFlo® Epidural System. However, the company acknowledges that its ability to continue as a going concern is contingent upon generating sufficient revenue and managing operating expenses effectively, alongside securing additional financing if necessary.